Most Read Articles
Tristan Manalac, 3 days ago
Of the newly identified genetic loci for primary angle-closure glaucoma (PACG), two are significantly associated with primary angle-closure suspect (PACS), indicating involvement in the earlier stages of the disease, a recent Singapore study has shown.
5 days ago
Use of proton pump inhibitors (PPIs), even at higher cumulative levels, does not increase the risk for dementia, a recent study has shown.
6 days ago
Persons with congenital heart disease (CHD) are at a higher risk of dementia, particularly early-onset dementia, than the general population, a recent study has shown.
Tristan Manalac, 5 days ago
Placebo pills, even when administered open-label, appear to significantly improve cancer-related fatigue and fatigue-disrupted quality of life, according to a recent study.

Bevacizumab dose-rounding policy leads to significant cost savings

12 Feb 2018

Rounding the dose of bevacizumab to the nearest vial size leads to substantial cost savings and does not significantly influence the incidence of adverse events, a recent study has found.

Between 1 August 2014 and 31 May 2016, 55 patients received at least one dose of bevacizumab, with a total of 470 doses administered to patients. Dose rounding of bevacizumab to the nearest 100 mg during the study time period led to an estimated cost savings of $164,617.92.

The rates of adverse events were comparable between patients who received either a dose that was rounded up or rounded down to the nearest 100 mg.

A retrospective chart review of all patients receiving at least one rounded dose of bevacizumab over a period of 22 months was conducted to assess potential cost savings incurred from such a policy and to determine difference in rates of adverse events among patients.

Bevacizumab doses were calculated based on actual body weight, and were then rounded to the nearest 400 or 100 mg vial size. The authors calculated the predicted effect on cost in US dollars for both the prerounded dose and the rounded dose.

Adverse events (eg, hypertension, proteinuria and vascular events) were compared between patients who received a dose that was rounded up and those with a dose rounded down.

Another study found that a practical dose down-rounding procedure was associated with a significant cost reduction in metastatic cancer setting, where the cure is not the goal. Drug waste could be prevented by convenient vial sized or could even be eliminated by lyophilized forms like in trastuzumab. [J Oncol Pharm Pract 2017;1:1078155217692400]

“Our data reflect the monoclonal antibody use and potential cost savings with the proposed dose down-rounding approach in a community-based cancer programme,” researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Tristan Manalac, 3 days ago
Of the newly identified genetic loci for primary angle-closure glaucoma (PACG), two are significantly associated with primary angle-closure suspect (PACS), indicating involvement in the earlier stages of the disease, a recent Singapore study has shown.
5 days ago
Use of proton pump inhibitors (PPIs), even at higher cumulative levels, does not increase the risk for dementia, a recent study has shown.
6 days ago
Persons with congenital heart disease (CHD) are at a higher risk of dementia, particularly early-onset dementia, than the general population, a recent study has shown.
Tristan Manalac, 5 days ago
Placebo pills, even when administered open-label, appear to significantly improve cancer-related fatigue and fatigue-disrupted quality of life, according to a recent study.